Author
Topics range from an analysis of recent developments in drug-pricing transparency, to an analysis of state-level drug product selection laws.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of December.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from November 2020.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from October 2020.
Selections feature topics ranging from political pressures facing the FDA, to the financial incentive structure for antibiotic development.
Interesting empirical studies, policy analyses, and editorials on pharma, health law, and policy issues from August 2020.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from July 2020.
Topics include challenges with false negative tests for SARS-CoV-2 infection and difficulties in implementing and enforcing state opioid prescribing laws.
Topics include the association between the clinical benefit of cancer drugs and their prices, and whether to include children in COVID-19 therapy trials.
The selections feature topics ranging from increases in Internet searches for hydroxychloroquine following promotional remarks by the president, to an evaluation of health gains from orphan drugs to an assessment of clinical trials supporting new FDA…
